A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.


Updates from The Motley Fool

Latest updates on Novavax from Fool.com.


Stock Performance

NVAX vs. S&P 500 | 2 Year Performance
View Interactive NVAX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Novavax.
Current Price: $7.00
Prev Close: $7.40
Open: $7.40
Bid: $7.04
Ask: $7.05
Day's Range: $6.97 - $7.59
52wk Range: $4.08 - $11.73
Volume: 4,296,434
Avg Vol 4,483,752
Market Cap: $1.89B
P/E (ttm): -7.40
EPS (ttm): -$1.00
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Novavax.
CAPS Rating 3 out of 5
 
319 Outperform
81 Underperform
CAPS All Stars
 
48 Outperform
15 Underperform

How do you think Novavax will perform against the market?



You pick for Novavax is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Stanley C. Erck, CEO

100% Approve

Based on 8 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Novavax.

A biopharmaceutical company focused on creating differentiated, value-added vaccines that improve upon current preventive options for a range of infectious diseases.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers